Enalapril-Teva 20 mg 30 tablets — Made in Poland — Free Delivery

Enalapril-Teva tablets are used for the following indications:

Treatment of arterial hypertension.

Treatment of clinically significant heart failure.

Prevention of clinically significant heart failure in patients with asymptomatic left ventricular dysfunction (ejection fraction ≤ 35%).

Active substance: enalapril maleate;

1 tablet contains 2.5 mg or 5 mg or 10 mg or 20 mg of enalapril maleate;

Excipients:

Tablets of 2.5 mg and 5 mg: lactose, corn starch, talc, sodium bicarbonate, hydroxypropyl cellulose, magnesium stearate;

Tablets of 10 mg and 20 mg: lactose, corn starch, talc, sodium bicarbonate, magnesium stearate, iron oxide red, iron oxide yellow (for tablets of 20 mg).

Hypersensitivity to enalapril, to any excipient or to any other ACE inhibitor.

A history of angioedema associated with the use of ACE inhibitors.

Hereditary or idiopathic angioedema.

Pregnant women or women planning to become pregnant.

Enalapril should not be used with drugs containing aliskiren in patients with diabetes mellitus or with impaired renal function (GFR <60 ml / min / 1.73 m 2).

Food intake does not affect the absorption of Enalapril-Teva tablets.

The dosage should be selected individually in accordance with the condition of each patient and the blood pressure response in response.

Contraindicated.

For use in children from 6 years of age.

Enalapril is not recommended for newborns and children with a glomerular filtration rate <30 ml / min / 1.73 m 2 due to lack of data.

When driving vehicles or other mechanisms, you should take into account the possible development of dizziness or increased fatigue.

There are limited data regarding drug overdose. The main signs of an overdose, according to the available data, are severe arterial hypotension, which begins approximately 6 hours after the use of the drug and coincides with a blockade of the renin-angiotensin system, and stupor. Symptoms associated with an ACE inhibitor overdose may include circulatory shock, electrolyte imbalance, renal failure, hyperventilation, tachycardia, heart palpitations, bradycardia, dizziness, anxiety, and coughing. Plasma levels of enalaprilat in excess of 100 and 200 times the maximum levels achieved with therapeutic doses have been reported after administration of 300 mg and 440 mg of enalapril, respectively.

For the treatment of overdose, intravenous infusion of isotonic solution is recommended. When arterial hypotension occurs, the patient should be laid down in a horizontal position. Consideration may be given to the need for angiotensin II infusions and / or intravenous catecholamines. If the drug has been recently taken, measures to eliminate enalapril maleate are recommended (such as artificial vomiting, gastric lavage, the use of absorbents and sodium sulfate). Enalaprilat can be removed from the systemic circulation by hemodialysis (see section "Peculiarities of use": patients on hemodialysis). For bradycardia resistant to therapeutic agents, therapy with a pacemaker is indicated. Important vital signs, electrolyte concentrations and serum creatinine levels should be monitored continuously.

When using enalapril, in most cases, side effects were minor, were temporary and did not require discontinuation of therapy.

From the blood system: anemia (including aplastic and hemolytic); neutropenia, decreased hemoglobin, decreased hematocrit, thrombocytopenia, agranulocytosis, bone marrow suppression, pancytopenia, lymphadenopathy, autoimmune diseases.

From the endocrine system: syndrome of impaired secretion of antidiuretic hormone.

Metabolic disorders: hypoglycemia (see section "Peculiarities of use").

From the nervous system and psyche: depression, headache; confusion, drowsiness, insomnia, nervousness, paresthesia, vertigo; sleep disorders, abnormal dreams.

From the side of the organs of vision: blurred vision.

On the part of the cardiovascular system: dizziness; hypotension (including orthostatic hypotension), syncope, chest pain, rhythm disturbance, angina pectoris, tachycardia; orthostatic hypotension, rapid heartbeat, myocardial infarction or stroke, possibly due to an excessive decrease in pressure in patients at high risk (see section "Peculiarities of use"), Raynaud's phenomenon.

From the respiratory system: cough; dyspnea; rhinorrhea, sore throat and hoarseness, bronchospasm / asthma; pulmonary infiltrates, rhinitis, allergic alveolitis / eosinophilic pneumonia.